Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Guillain-Barre Syndrome
NCT02029378Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Sep 2014
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Guillain-Barré syndrome (GBS) comparing Eculizumab with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 6 months and Improvement of one or more grade in functional outcome on GBS disability scale at 4 weeks. Status: unknown.
02
Drugs
eculizumab
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT02029378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029378.